NZ528322A

NZ528322A - Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's

Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases such as alzheimer's disease and parkinson's

Info

Publication number: NZ528322A
Authority: NZ; New Zealand
Prior art keywords: epicatechin; proanthocyanidin; amyloid; formula; proanthocyanidins
Prior art date: 2001-03-15

Application number

NZ528322A

Other languages

English (en)

Inventor

Alan D Snow

Geraldo M Castillo

Paula Y Choi

Beth P Nguyen

Original Assignee

Proteotech Inc

Priority date

2001-03-15

Filing date

2002-02-15

Publication date

2005-03-24

2001-08-24 Priority claimed from US09/938,987 external-priority patent/US6607758B2/en

2001-11-02 Priority claimed from US10/053,625 external-priority patent/US6929808B2/en

2002-02-15 Application filed by Proteotech Inc filed Critical Proteotech Inc

2005-03-24 Publication of NZ528322A publication Critical patent/NZ528322A/en

Links

229920002770 condensed tannin Polymers 0.000 title claims abstract description 138
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 82
238000011282 treatment Methods 0.000 title claims abstract description 74
201000010099 disease Diseases 0.000 title claims abstract description 68
102000003802 alpha-Synuclein Human genes 0.000 title abstract description 4
108090000185 alpha-Synuclein Proteins 0.000 title abstract description 4
208000024827 Alzheimer disease Diseases 0.000 title description 82
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 184
229920001991 Proanthocyanidin Polymers 0.000 claims abstract description 141
JPFCOVZKLAXXOE-XBNSMERZSA-N (3r)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2r,3r,4r)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2h-chromen-4-yl]-3,4-dihydro-2h-chromene-3,5,7-triol Chemical compound C1=C(O)C(OC)=C(O)C=C1C1[C@H](O)CC(C(O)=CC(O)=C2[C@H]3C4=C(O)C=C(O)C=C4O[C@@H]([C@@H]3O)C=3C=CC(O)=CC=3)=C2O1 JPFCOVZKLAXXOE-XBNSMERZSA-N 0.000 claims abstract description 137
238000000034 method Methods 0.000 claims abstract description 136
206010002022 amyloidosis Diseases 0.000 claims abstract description 103
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 83
PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical group C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims abstract description 77
235000012734 epicatechin Nutrition 0.000 claims abstract description 71
PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Chemical group C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims abstract description 70
LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Chemical group Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims abstract description 70
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical group C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 58
229950001002 cianidanol Drugs 0.000 claims abstract description 58
ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Chemical group OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims abstract description 56
235000005487 catechin Nutrition 0.000 claims abstract description 56
239000000284 extract Substances 0.000 claims abstract description 50
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 48
239000000463 material Substances 0.000 claims abstract description 44
230000035557 fibrillogenesis Effects 0.000 claims abstract description 43
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 37
239000001257 hydrogen Substances 0.000 claims abstract description 37
229910002027 silica gel Inorganic materials 0.000 claims abstract description 36
239000000741 silica gel Substances 0.000 claims abstract description 36
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
238000000338 in vitro Methods 0.000 claims abstract description 15
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 13
125000003107 substituted aryl group Chemical group 0.000 claims abstract description 13
238000004108 freeze drying Methods 0.000 claims abstract description 7
238000011068 loading method Methods 0.000 claims abstract description 7
238000004007 reversed phase HPLC Methods 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 120
CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 claims description 73
229920002414 procyanidin Polymers 0.000 claims description 73
241000196324 Embryophyta Species 0.000 claims description 69
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 60
XFZJEEAOWLFHDH-UHFFFAOYSA-N (2R,2'R,3R,3'R,4R)-3,3',4',5,7-Pentahydroxyflavan(48)-3,3',4',5,7-pentahydroxyflavan Natural products C=12OC(C=3C=C(O)C(O)=CC=3)C(O)CC2=C(O)C=C(O)C=1C(C1=C(O)C=C(O)C=C1O1)C(O)C1C1=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UHFFFAOYSA-N 0.000 claims description 54
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 52
HGVVOUNEGQIPMS-UHFFFAOYSA-N procyanidin Chemical compound O1C2=CC(O)=CC(O)=C2C(O)C(O)C1(C=1C=C(O)C(O)=CC=1)OC1CC2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 HGVVOUNEGQIPMS-UHFFFAOYSA-N 0.000 claims description 52
235000011472 cat’s claw Nutrition 0.000 claims description 49
241000607122 Uncaria tomentosa Species 0.000 claims description 44
MOJZMWJRUKIQGL-FWCKPOPSSA-N Procyanidin C2 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@H]3[C@H](O)[C@@H](c4cc(O)c(O)cc4)Oc4c3c(O)cc(O)c4)c(O)cc(O)c2[C@@H]1c1c(O)cc(O)c2c1O[C@@H]([C@H](O)C2)c1cc(O)c(O)cc1 MOJZMWJRUKIQGL-FWCKPOPSSA-N 0.000 claims description 38
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 34
RSYUFYQTACJFML-UKRRQHHQSA-N (-)-epiafzelechin Chemical group C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-UKRRQHHQSA-N 0.000 claims description 33
239000013638 trimer Substances 0.000 claims description 33
238000002955 isolation Methods 0.000 claims description 31
239000000539 dimer Substances 0.000 claims description 25
239000000546 pharmaceutical excipient Substances 0.000 claims description 24
230000001225 therapeutic effect Effects 0.000 claims description 21
150000003839 salts Chemical class 0.000 claims description 19
229920000429 procyanidin dimer Polymers 0.000 claims description 18
238000006467 substitution reaction Methods 0.000 claims description 14
230000037396 body weight Effects 0.000 claims description 11
239000003814 drug Substances 0.000 claims description 11
230000008569 process Effects 0.000 claims description 11
239000003085 diluting agent Substances 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
125000004403 catechin group Chemical group 0.000 claims description 6
125000004356 hydroxy functional group Chemical group O* 0.000 claims 4
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 170
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 13
102100031639 Nascent polypeptide-associated complex subunit alpha Human genes 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
108010037351 nascent-polypeptide-associated complex Proteins 0.000 abstract 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
230000003941 amyloidogenesis Effects 0.000 description 54
208000018737 Parkinson disease Diseases 0.000 description 47
238000004128 high performance liquid chromatography Methods 0.000 description 45
208000001072 type 2 diabetes mellitus Diseases 0.000 description 43
102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 40
108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 40
238000009825 accumulation Methods 0.000 description 36
-1 aromatic polyphenols compounds Chemical class 0.000 description 35
230000002401 inhibitory effect Effects 0.000 description 33
230000000694 effects Effects 0.000 description 29
238000000151 deposition Methods 0.000 description 28
102000001049 Amyloid Human genes 0.000 description 27
108010094108 Amyloid Proteins 0.000 description 27
230000002688 persistence Effects 0.000 description 27
230000015572 biosynthetic process Effects 0.000 description 26
238000005755 formation reaction Methods 0.000 description 26
210000004556 brain Anatomy 0.000 description 25
108090000623 proteins and genes Proteins 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 25
230000003389 potentiating effect Effects 0.000 description 24
238000005481 NMR spectroscopy Methods 0.000 description 23
230000035508 accumulation Effects 0.000 description 23
239000003795 chemical substances by application Substances 0.000 description 23
206010002023 Amyloidoses Diseases 0.000 description 22
125000004387 flavanoid group Chemical group 0.000 description 22
239000002904 solvent Substances 0.000 description 22
210000003719 b-lymphocyte Anatomy 0.000 description 21
238000001228 spectrum Methods 0.000 description 21
235000013824 polyphenols Nutrition 0.000 description 20
230000007082 Aβ accumulation Effects 0.000 description 19
235000019506 cigar Nutrition 0.000 description 19
239000000243 solution Substances 0.000 description 19
230000009885 systemic effect Effects 0.000 description 19
238000011534 incubation Methods 0.000 description 18
206010012601 diabetes mellitus Diseases 0.000 description 17
230000008021 deposition Effects 0.000 description 16
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 16
150000008442 polyphenolic compounds Chemical class 0.000 description 16
XFZJEEAOWLFHDH-NFJBMHMQSA-N procyanidin B2 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-NFJBMHMQSA-N 0.000 description 16
239000000725 suspension Substances 0.000 description 16
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
208000037259 Amyloid Plaque Diseases 0.000 description 15
231100000673 dose–response relationship Toxicity 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
229910052799 carbon Inorganic materials 0.000 description 14
150000002206 flavan-3-ols Chemical class 0.000 description 14
229920000642 polymer Polymers 0.000 description 14
239000003826 tablet Substances 0.000 description 14
JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 14
238000000926 separation method Methods 0.000 description 13
208000023769 AA amyloidosis Diseases 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
230000036961 partial effect Effects 0.000 description 12
102000013455 Amyloid beta-Peptides Human genes 0.000 description 11
108010090849 Amyloid beta-Peptides Proteins 0.000 description 11
108010048112 Amyloidogenic Proteins Proteins 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 11
230000021736 acetylation Effects 0.000 description 11
238000006640 acetylation reaction Methods 0.000 description 11
238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 11
238000002474 experimental method Methods 0.000 description 11
239000007788 liquid Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
125000001424 substituent group Chemical group 0.000 description 11
238000012360 testing method Methods 0.000 description 11
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 10
208000009829 Lewy Body Disease Diseases 0.000 description 10
201000002832 Lewy body dementia Diseases 0.000 description 10
108010071690 Prealbumin Proteins 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
244000269722 Thea sinensis Species 0.000 description 10
241000157352 Uncaria Species 0.000 description 10
230000008878 coupling Effects 0.000 description 10
238000010168 coupling process Methods 0.000 description 10
238000005859 coupling reaction Methods 0.000 description 10
238000010828 elution Methods 0.000 description 10
239000000839 emulsion Substances 0.000 description 10
230000036541 health Effects 0.000 description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
238000002360 preparation method Methods 0.000 description 10
238000000746 purification Methods 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
102000009091 Amyloidogenic Proteins Human genes 0.000 description 9
229920002350 Procyanidin B2 Polymers 0.000 description 9
229920001505 Procyanidin B4 Polymers 0.000 description 9
238000004440 column chromatography Methods 0.000 description 9
235000013305 food Nutrition 0.000 description 9
239000003112 inhibitor Substances 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
150000002500 ions Chemical class 0.000 description 9
239000000178 monomer Substances 0.000 description 9
108090000765 processed proteins & peptides Proteins 0.000 description 9
229920001864 tannin Polymers 0.000 description 9
235000018553 tannin Nutrition 0.000 description 9
239000001648 tannin Substances 0.000 description 9
241000124008 Mammalia Species 0.000 description 8
208000001089 Multiple system atrophy Diseases 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
238000003556 assay Methods 0.000 description 8
IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
238000004090 dissolution Methods 0.000 description 8
150000002148 esters Chemical class 0.000 description 8
230000008506 pathogenesis Effects 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
XFZJEEAOWLFHDH-RBYKNZBFSA-N Procyanidin B4 Natural products O[C@@H]1[C@@H](c2cc(O)c(O)cc2)Oc2c([C@@H]1c1c(O)cc(O)c3c1O[C@H]([C@@H](O)C3)c1cc(O)c(O)cc1)c(O)cc(O)c2 XFZJEEAOWLFHDH-RBYKNZBFSA-N 0.000 description 7
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
125000003118 aryl group Chemical group 0.000 description 7
238000004587 chromatography analysis Methods 0.000 description 7
238000000605 extraction Methods 0.000 description 7
238000005558 fluorometry Methods 0.000 description 7
238000001631 haemodialysis Methods 0.000 description 7
230000000322 hemodialysis Effects 0.000 description 7
201000001421 hyperglycemia Diseases 0.000 description 7
210000003000 inclusion body Anatomy 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
230000007774 longterm Effects 0.000 description 7
230000003340 mental effect Effects 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
XFZJEEAOWLFHDH-VUGKQVTMSA-N procyanidin B4 Chemical compound C1([C@@H]2[C@@H](O)[C@@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-VUGKQVTMSA-N 0.000 description 7
239000000047 product Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
235000020357 syrup Nutrition 0.000 description 7
239000006188 syrup Substances 0.000 description 7
235000013616 tea Nutrition 0.000 description 7
208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 6
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 6
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 6
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 6
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
201000010374 Down Syndrome Diseases 0.000 description 6
206010016207 Familial Mediterranean fever Diseases 0.000 description 6
208000034578 Multiple myelomas Diseases 0.000 description 6
206010035226 Plasma cell myeloma Diseases 0.000 description 6
206010036105 Polyneuropathy Diseases 0.000 description 6
206010044688 Trisomy 21 Diseases 0.000 description 6
239000000443 aerosol Substances 0.000 description 6
229930013930 alkaloid Natural products 0.000 description 6
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
239000000872 buffer Substances 0.000 description 6
244000309464 bull Species 0.000 description 6
201000011510 cancer Diseases 0.000 description 6
208000003295 carpal tunnel syndrome Diseases 0.000 description 6
150000001765 catechin Chemical class 0.000 description 6
XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
206010023497 kuru Diseases 0.000 description 6
210000004558 lewy body Anatomy 0.000 description 6
230000014759 maintenance of location Effects 0.000 description 6
230000036210 malignancy Effects 0.000 description 6
238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 6
125000004095 oxindolyl group Chemical class N1(C(CC2=CC=CC=C12)=O)* 0.000 description 6
239000006187 pill Substances 0.000 description 6
230000007824 polyneuropathy Effects 0.000 description 6
239000002243 precursor Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
235000014161 Caesalpinia gilliesii Nutrition 0.000 description 5
244000003240 Caesalpinia gilliesii Species 0.000 description 5
208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
102000004877 Insulin Human genes 0.000 description 5
108090001061 Insulin Proteins 0.000 description 5
208000024777 Prion disease Diseases 0.000 description 5
102000009190 Transthyretin Human genes 0.000 description 5
102100029290 Transthyretin Human genes 0.000 description 5
230000032683 aging Effects 0.000 description 5
102000015736 beta 2-Microglobulin Human genes 0.000 description 5
108010081355 beta 2-Microglobulin Proteins 0.000 description 5
239000011575 calcium Substances 0.000 description 5
208000037976 chronic inflammation Diseases 0.000 description 5
230000006020 chronic inflammation Effects 0.000 description 5
239000007859 condensation product Substances 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
150000004665 fatty acids Chemical class 0.000 description 5
239000000796 flavoring agent Substances 0.000 description 5
229920000591 gum Polymers 0.000 description 5
229940125396 insulin Drugs 0.000 description 5
239000007937 lozenge Substances 0.000 description 5
XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 5
230000035772 mutation Effects 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
239000000843 powder Substances 0.000 description 5
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
208000008864 scrapie Diseases 0.000 description 5
238000010898 silica gel chromatography Methods 0.000 description 5
239000000377 silicon dioxide Substances 0.000 description 5
239000000829 suppository Substances 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
235000007219 (+)-catechin Nutrition 0.000 description 4
229930013915 (+)-catechin Natural products 0.000 description 4
208000018282 ACys amyloidosis Diseases 0.000 description 4
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 4
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 4
CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 4
230000002378 acidificating effect Effects 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000002776 aggregation Effects 0.000 description 4
238000004220 aggregation Methods 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
239000007894 caplet Substances 0.000 description 4
230000000747 cardiac effect Effects 0.000 description 4
150000001793 charged compounds Chemical class 0.000 description 4
238000000978 circular dichroism spectroscopy Methods 0.000 description 4
201000011523 endocrine gland cancer Diseases 0.000 description 4
235000011987 flavanols Nutrition 0.000 description 4
HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 4
235000011957 flavonols Nutrition 0.000 description 4
235000013355 food flavoring agent Nutrition 0.000 description 4
235000003599 food sweetener Nutrition 0.000 description 4
238000009472 formulation Methods 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
238000001819 mass spectrum Methods 0.000 description 4
208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 4
239000013642 negative control Substances 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
210000000496 pancreas Anatomy 0.000 description 4
238000007911 parenteral administration Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
235000009048 phenolic acids Nutrition 0.000 description 4
150000007965 phenolic acids Chemical class 0.000 description 4
235000020004 porter Nutrition 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000000750 progressive effect Effects 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
239000000375 suspending agent Substances 0.000 description 4
239000003765 sweetening agent Substances 0.000 description 4
208000011580 syndromic disease Diseases 0.000 description 4
238000011830 transgenic mouse model Methods 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
235000007355 (-)-epicatechin Nutrition 0.000 description 3
229930013783 (-)-epicatechin Natural products 0.000 description 3
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
238000012584 2D NMR experiment Methods 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
101150041968 CDC13 gene Proteins 0.000 description 3
208000005623 Carcinogenesis Diseases 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
101100286193 Homo sapiens IAPP gene Proteins 0.000 description 3
XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 3
240000006236 Martynia annua Species 0.000 description 3
102000007079 Peptide Fragments Human genes 0.000 description 3
108010033276 Peptide Fragments Proteins 0.000 description 3
235000019096 Proboscidea parviflora Nutrition 0.000 description 3
108010048233 Procalcitonin Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102000019355 Synuclein Human genes 0.000 description 3
108050006783 Synuclein Proteins 0.000 description 3
235000009470 Theobroma cacao Nutrition 0.000 description 3
244000299461 Theobroma cacao Species 0.000 description 3
230000036626 alertness Effects 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
229930014669 anthocyanidin Natural products 0.000 description 3
235000008758 anthocyanidins Nutrition 0.000 description 3
230000008901 benefit Effects 0.000 description 3
210000004204 blood vessel Anatomy 0.000 description 3
230000036952 cancer formation Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
150000001721 carbon Chemical group 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000030833 cell death Effects 0.000 description 3
208000015114 central nervous system disease Diseases 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
238000002983 circular dichroism Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003086 colorant Substances 0.000 description 3
230000006735 deficit Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
235000013399 edible fruits Nutrition 0.000 description 3
DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 3
230000005284 excitation Effects 0.000 description 3
229930182497 flavan-3-ol Natural products 0.000 description 3
NWKFECICNXDNOQ-UHFFFAOYSA-N flavylium Chemical compound C1=CC=CC=C1C1=CC=C(C=CC=C2)C2=[O+]1 NWKFECICNXDNOQ-UHFFFAOYSA-N 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000008103 glucose Substances 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000002452 interceptive effect Effects 0.000 description 3
210000004153 islets of langerhan Anatomy 0.000 description 3
235000010445 lecithin Nutrition 0.000 description 3
239000000787 lecithin Substances 0.000 description 3
229940067606 lecithin Drugs 0.000 description 3
229940057995 liquid paraffin Drugs 0.000 description 3
230000015654 memory Effects 0.000 description 3
229930014626 natural product Natural products 0.000 description 3
208000015122 neurodegenerative disease Diseases 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
239000003921 oil Substances 0.000 description 3
235000019198 oils Nutrition 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000008177 pharmaceutical agent Substances 0.000 description 3
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 3
239000012058 sterile packaged powder Substances 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
235000006491 Acacia senegal Nutrition 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
101710170564 Bradykinin-potentiating peptide Proteins 0.000 description 2
PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
206010012289 Dementia Diseases 0.000 description 2
244000236655 Diospyros kaki Species 0.000 description 2
235000008597 Diospyros kaki Nutrition 0.000 description 2
229940124602 FDA-approved drug Drugs 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
235000019759 Maize starch Nutrition 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
229920000124 Prodelphinidin Polymers 0.000 description 2
229930182448 Prodelphinidin Natural products 0.000 description 2
229920002783 Propelargonidin Polymers 0.000 description 2
REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
101100286200 Rattus norvegicus Iapp gene Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
229920001615 Tragacanth Polymers 0.000 description 2
JMIAZDVHNCCPDM-PFDNRQJHSA-N Uncarine E Chemical compound O=C1NC2=CC=CC=C2[C@]11CCN2C[C@H]3[C@H](C)OC=C(C(=O)OC)[C@H]3C[C@H]21 JMIAZDVHNCCPDM-PFDNRQJHSA-N 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000009471 action Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229930002877 anthocyanin Natural products 0.000 description 2
235000010208 anthocyanin Nutrition 0.000 description 2
239000004410 anthocyanin Substances 0.000 description 2
150000004636 anthocyanins Chemical class 0.000 description 2
230000003217 anti-cancerogenic effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
239000002585 base Substances 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
230000003925 brain function Effects 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
235000010216 calcium carbonate Nutrition 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
235000001368 chlorogenic acid Nutrition 0.000 description 2
229940074393 chlorogenic acid Drugs 0.000 description 2
FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
239000000544 cholinesterase inhibitor Substances 0.000 description 2
238000001142 circular dichroism spectrum Methods 0.000 description 2
BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
230000019771 cognition Effects 0.000 description 2
230000006999 cognitive decline Effects 0.000 description 2
208000010877 cognitive disease Diseases 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
230000007370 cognitive improvement Effects 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
210000004395 cytoplasmic granule Anatomy 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
230000007850 degeneration Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
230000001627 detrimental effect Effects 0.000 description 2
230000008034 disappearance Effects 0.000 description 2
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
150000005835 flavan-3,4-diols Chemical class 0.000 description 2
150000007946 flavonol Chemical class 0.000 description 2
150000002216 flavonol derivatives Chemical class 0.000 description 2
235000004515 gallic acid Nutrition 0.000 description 2
229940074391 gallic acid Drugs 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000005227 gel permeation chromatography Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
229930182470 glycoside Natural products 0.000 description 2
150000002338 glycosides Chemical class 0.000 description 2
125000003147 glycosyl group Chemical group 0.000 description 2
239000008187 granular material Substances 0.000 description 2
235000009569 green tea Nutrition 0.000 description 2
238000005570 heteronuclear single quantum coherence Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 description 2
ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
210000002660 insulin-secreting cell Anatomy 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000036997 mental performance Effects 0.000 description 2
239000000401 methanolic extract Substances 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
230000001537 neural effect Effects 0.000 description 2
230000002887 neurotoxic effect Effects 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
239000012457 nonaqueous media Substances 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
230000003204 osmotic effect Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
230000004203 pancreatic function Effects 0.000 description 2
230000007170 pathology Effects 0.000 description 2
239000002831 pharmacologic agent Substances 0.000 description 2
239000008196 pharmacological composition Substances 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000002265 prevention Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000006916 protein interaction Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
235000011069 sorbitan monooleate Nutrition 0.000 description 2
239000001593 sorbitan monooleate Substances 0.000 description 2
229940035049 sorbitan monooleate Drugs 0.000 description 2
238000010186 staining Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
238000011287 therapeutic dose Methods 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
230000009261 transgenic effect Effects 0.000 description 2
235000015112 vegetable and seed oil Nutrition 0.000 description 2
239000008158 vegetable oil Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
238000001262 western blot Methods 0.000 description 2
XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
CSCPPACGZOOCGX-MICDWDOJSA-N 1-deuteriopropan-2-one Chemical compound [2H]CC(C)=O CSCPPACGZOOCGX-MICDWDOJSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
PBZMVAYHJDFHIR-UHFFFAOYSA-N 2-phenyl-3,4-dihydrochromene-2,3-diol Chemical class OC1CC2=CC=CC=C2OC1(O)C1=CC=CC=C1 PBZMVAYHJDFHIR-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
229920001722 A-type proanthocyanidin Polymers 0.000 description 1
208000023761 AL amyloidosis Diseases 0.000 description 1
101150054866 Acadl gene Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000025298 Alzheimer disease 15 Diseases 0.000 description 1
208000012920 Alzheimer disease without neurofibrillary tangles Diseases 0.000 description 1
235000006226 Areca catechu Nutrition 0.000 description 1
244000080767 Areca catechu Species 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007509 Cardiac amyloidosis Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
229920002079 Ellagic acid Polymers 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
108050001049 Extracellular proteins Proteins 0.000 description 1
OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
240000005979 Hordeum vulgare Species 0.000 description 1
235000007340 Hordeum vulgare Nutrition 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
241001071861 Lethrinus genivittatus Species 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000220225 Malus Species 0.000 description 1
235000011430 Malus pumila Nutrition 0.000 description 1
235000015103 Malus silvestris Nutrition 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
238000012565 NMR experiment Methods 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000002774 Paraproteinemias Diseases 0.000 description 1
208000018639 Parkinson disease 20 Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
235000006089 Phaseolus angularis Nutrition 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241000108402 Pteropoda Species 0.000 description 1
ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000219061 Rheum Species 0.000 description 1
244000299790 Rheum rhabarbarum Species 0.000 description 1
235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
235000011034 Rubus glaucus Nutrition 0.000 description 1
235000009122 Rubus idaeus Nutrition 0.000 description 1
102000054727 Serum Amyloid A Human genes 0.000 description 1
108700028909 Serum Amyloid A Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
235000006468 Thea sinensis Nutrition 0.000 description 1
241000656145 Thyrsites atun Species 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
240000004840 Uncaria attenuata Species 0.000 description 1
244000056892 Uncaria elliptica Species 0.000 description 1
244000081822 Uncaria gambir Species 0.000 description 1
241000683228 Uncaria guianensis Species 0.000 description 1
240000001717 Vaccinium macrocarpon Species 0.000 description 1
235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
235000002118 Vaccinium oxycoccus Nutrition 0.000 description 1
235000010711 Vigna angularis Nutrition 0.000 description 1
240000007098 Vigna angularis Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
235000009754 Vitis X bourquina Nutrition 0.000 description 1
235000012333 Vitis X labruscana Nutrition 0.000 description 1
240000006365 Vitis vinifera Species 0.000 description 1
235000014787 Vitis vinifera Nutrition 0.000 description 1
238000002441 X-ray diffraction Methods 0.000 description 1
WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
229940039856 aricept Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
235000021028 berry Nutrition 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
235000020279 black tea Nutrition 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
230000036995 brain health Effects 0.000 description 1
230000000981 bystander Effects 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
150000007942 carboxylates Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000003930 cognitive ability Effects 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
235000004634 cranberry Nutrition 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000000120 cytopathologic effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
235000019221 dark chocolate Nutrition 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
229940126534 drug product Drugs 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
208000018620 early-onset Parkinson disease Diseases 0.000 description 1
208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
235000004132 ellagic acid Nutrition 0.000 description 1
229960002852 ellagic acid Drugs 0.000 description 1
229920001968 ellagitannin Polymers 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
229940030275 epigallocatechin gallate Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
208000015756 familial Alzheimer disease Diseases 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000010304 firing Methods 0.000 description 1
QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical group C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229940068517 fruit extracts Drugs 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
229920002824 gallotannin Polymers 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002518 glial effect Effects 0.000 description 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
UHUSDOQQWJGJQS-UHFFFAOYSA-N glycerol 1,2-dioctadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCCCCCCCCCC UHUSDOQQWJGJQS-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
231100000304 hepatotoxicity Toxicity 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
229920001461 hydrolysable tannin Polymers 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
229930182489 iridoid glycoside Natural products 0.000 description 1
150000008145 iridoid glycosides Chemical class 0.000 description 1
RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000028252 learning or memory Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
235000020094 liqueur Nutrition 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000007056 liver toxicity Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000008897 memory decline Effects 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
235000020069 metaxa Nutrition 0.000 description 1
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
239000005445 natural material Substances 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
230000016273 neuron death Effects 0.000 description 1
230000006764 neuronal dysfunction Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
230000001019 normoglycemic effect Effects 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229930182677 oxindole alkaloid Natural products 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
102000045222 parkin Human genes 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000008756 pathogenetic mechanism Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
235000017807 phytochemicals Nutrition 0.000 description 1
229930000223 plant secondary metabolite Natural products 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229940124606 potential therapeutic agent Drugs 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
XFZJEEAOWLFHDH-UKWJTHFESA-N procyanidin B1 Chemical compound C1([C@@H]2[C@H](O)[C@H](C3=C(O)C=C(O)C=C3O2)C=2C(O)=CC(O)=C3C[C@@H]([C@H](OC3=2)C=2C=C(O)C(O)=CC=2)O)=CC=C(O)C(O)=C1 XFZJEEAOWLFHDH-UKWJTHFESA-N 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000003586 protic polar solvent Substances 0.000 description 1
239000010453 quartz Substances 0.000 description 1
235000005875 quercetin Nutrition 0.000 description 1
229960001285 quercetin Drugs 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
235000020095 red wine Nutrition 0.000 description 1
238000012552 review Methods 0.000 description 1
238000002390 rotary evaporation Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
229960003565 tacrine hydrochloride Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
235000014101 wine Nutrition 0.000 description 1